William Blair analyst Raju Prasad downgrades Precision BioSciences (NASDAQ:DTIL) from Outperform to Market Perform.
B. Riley Securities Maintains Buy on Harrow Health, Raises Price Target to $20
B. Riley Securities analyst Justin Walsh maintains Harrow Health (NASDAQ:HROW) with a Buy and raises the price target from $17 to $20.